

In the Claims:

1. (Currently Amended) A system for iontophoretic transdermal delivery of one or more therapeutic agents into a user's skin, comprising:

a first end comprising a first reservoir for containing one or more therapeutic agents;

a second end comprising a second reservoir for containing one or more therapeutic agents; and

~~a connecting portion coupling the first end to the second end, the connecting portion housing:~~

a self-contained power source for generating electric current, the power source comprising a first terminal and a second terminal;

~~at least a portion of a first electrode for~~ adapted to electrically coupling couple the first terminal of the power source to the first reservoir, the first electrode operable to conduct electric current between the power source and the first reservoir to ~~ionize~~ promote iontophoretic transdermal delivery of the one or more therapeutic agents contained within the first reservoir ~~for iontophoretic transdermal delivery~~ into the user's skin; and

~~at least a portion of a second electrode for~~ adapted to electrically coupling couple the second terminal of the power source to the second reservoir, the second electrode operable to conduct electric current between the power source and the second reservoir to ~~ionize~~ promote iontophoretic transdermal delivery of the one or more therapeutic agents contained within the second reservoir ~~for iontophoretic transdermal delivery~~ into the user's skin; and

a foldable connecting portion coupling the first end to the second end and adapted to allow the system adapted to be used in an extended or non-extended state, in the extended state the first and second ends being separated by a first predetermined distance with the connecting portion in an unfolded configuration, in the non-extended state the first and second ends being separated by a second distance less than the first distance with the connecting portion in a folded configuration.

2. (Original) The system of Claim 1, wherein the first and second reservoirs are adapted to deliver one or more therapeutic agents to one or more portions of a user's body substantially simultaneously.

3. (Original) The system of Claim 1, further comprising a protective covering associated with the connecting portion and adapted to be removably coupled to a hypoallergenic adhesive on a bottom of the connecting portion, the hypoallergenic adhesive adapted to removably couple the system to a portion of the user's body.

4. (Original) The system of Claim 1, further comprising a protective tab associated with each reservoir, each tab adapted to be removably coupled to a hypoallergenic adhesive associated with its reservoir and further adapted to protect and provide protection from the therapeutic agents in its reservoir during application of the system to the user's skin, the hypoallergenic adhesive adapted to removably couple the system to a portion of the user's body.

5. (Original) The system of Claim 1, wherein the first end is associated with a positive terminal of the power source and the second end is associated with a negative terminal of the power source.

6. (Original) The system of Claim 1, wherein each reservoir comprises:  
a reservoir pad adapted to absorb the therapeutic agents to be delivered to the user;  
and  
a reservoir gasket adapted to help contain the therapeutic agents contained in the reservoir pad.

7. (Original) The system of Claim 6, wherein the reservoir gaskets comprise a soft, flexible, foldable, FDA-approved, hypoallergenic foam material.

8. (Original) The system of Claim 6, wherein the reservoir pads comprise a soft, flexible, foldable, absorbent, FDA-approved, hypoallergenic material.

9. (Original) The system of Claim 1, wherein the self-contained power source is a battery.

10. (Original) The system of Claim 9, wherein the battery is a 1.55 volt battery.

11. (Original) The system of Claim 1, wherein the first electrode, the second electrode, and the power source comprise a flex-circuit.

12. (Original) The system of Claim 11, further comprising a hidden pocket disposed on the first or second end and adapted to house the connecting portion and at least a portion of the flex-circuit when the system is in the non-extended state.

13. (Original) The system of Claim 1, wherein the system is adapted to be disposable after a single use.

14. (Original) The system of Claim 1, wherein the power source is insulated in a protective covering.

15. (Original) The system of Claim 14, wherein the protective covering is made from a polymer or gel-like substance.

16. (Original) The system of Claim 1, wherein the first electrode, the second electrode, and the power source are disposed between at least one layer of insulating material to protect the user's skin.

17. (Original) The system of Claim 1, wherein the system has a maximum thickness of approximately one-sixteenth of an inch.

18. (Currently Amended) A method for manufacturing a system for iontophoretic transdermal delivery of one or more therapeutic agents into a user's skin, comprising:

providing a first reservoir for containing one or more therapeutic agents;

providing a second reservoir for containing one or more therapeutic agents;

providing a self-contained power source for generating electric current, the power source comprising a first terminal and a second terminal;

providing a first electrode ~~for~~ adapted to electrically ~~coupling~~ couple the first terminal of the power source to the first reservoir, the first electrode operable to conduct electric current between the power source and the first reservoir to ~~ionize~~ promote iontophoretic transdermal delivery of the one or more therapeutic agents contained within the first reservoir ~~for iontophoretic transdermal delivery~~ into the user's skin; and

providing a second electrode ~~for~~ adapted to electrically ~~coupling~~ couple the second terminal of the power source to the second reservoir, the second electrode operable to conduct electric current between the power source and the second reservoir to ~~ionize~~ promote iontophoretic transdermal delivery of the one or more therapeutic agents contained within the second reservoir ~~for iontophoretic transdermal delivery~~ into the user's skin; and

providing a foldable connecting portion coupling the first reservoir to the second reservoir and the system adapted to be used in an extended or non-extended state, in the extended state the first and second reservoirs being separated by a first predetermined distance with the connecting portion in an unfolded configuration, in the non-extended state the first and second reservoirs being separated by a second distance less than the first distance with the connecting portion in a folded configuration.

19. (Original) The method of Claim 18, wherein the first and second reservoirs are adapted to deliver one or more therapeutic agents to one or more portions of a user's body substantially simultaneously.

20. (Currently Amended) The ~~system~~ method of Claim 18, further comprising providing a protective covering associated with the connecting portion and adapted to be removably coupled to a hypoallergenic adhesive on a bottom of the connecting portion, the hypoallergenic adhesive adapted to removably couple the system to a portion of the user's body.

21. (Original) The method of Claim 18, further comprising providing a protective tab associated with each reservoir, each tab adapted to be removably coupled to a hypoallergenic adhesive associated with its reservoir and further adapted to protect and provide protection from the therapeutic agents in its reservoir during application of the system to the user's skin, the hypoallergenic adhesive adapted to removably couple the system to a portion of the user's body.

22. (Original) The method of Claim 18, wherein the first end is associated with a positive terminal of the power source and the second end is associated with a negative terminal of the power source.

23. (Original) The method of Claim 18, further comprising:  
providing for each reservoir a reservoir pad adapted to absorb the therapeutic agents to be delivered to the user; and  
providing for each reservoir a reservoir gasket adapted to help contain the therapeutic agents contained in the reservoir pad.

24. (Original) The method of Claim 23, wherein the reservoir gaskets comprise a soft, flexible, foldable, FDA-approved, hypoallergenic foam material.

25. (Original) The method of Claim 23, wherein the reservoir pads comprise a soft, flexible, foldable, absorbent, FDA-approved, hypoallergenic material.

26. (Original) The method of Claim 18, wherein the self-contained power source is a battery.

27. (Original) The method of Claim 26, wherein the battery is a 1.55 volt battery.

28. (Original) The method of Claim 18, wherein the first electrode, the second electrode, and the power source comprise a flex-circuit.

29. (Original) The method of Claim 28, further comprising providing a hidden pocket disposed on the first or second end and adapted to house the connecting portion and at least a portion of the flex-circuit when the system is in the non-extended state.

30. (Original) The method of Claim 18, wherein the system is adapted to be disposable after a single use.

31. (Original) The method of Claim 18, further comprising providing a protective covering to insulate the power source.

32. (Original) The method of Claim 31, wherein the protective covering is made from a polymer or gel-like substance.

33. (Original) The method of Claim 18, further comprising providing at least one layer of insulating material disposed about the first electrode, the second electrode, and the power source, the insulating material adapted to protect the user's skin.

34. (Currently Amended) The ~~system~~ method of Claim 18, wherein the system has a maximum thickness of approximately one-sixteenth of an inch.

35. (Currently Amended) A method for delivering one or more therapeutic agents to a user through the user's skin, comprising:

positioning an iontophoretic transdermal delivery system about a portion of the user's body to receive treatment, the system ~~adapted to be used in an extended or non-extended state~~ and comprising:

a first end comprising a first reservoir for containing one or more therapeutic agents;

a second end comprising a second reservoir for containing one or more therapeutic agents; and

~~a connecting portion coupling the first end to the second end, the connecting portion housing:~~

a self-contained power source for generating electric current, the power source comprising a first terminal and a second terminal;

a first electrode ~~for~~ adapted to electrically ~~coupling~~ couple the first terminal of the power source to the first reservoir, the first electrode operable to conduct electric current between the power source and the first reservoir to ~~ionize~~ promote iontophoretic transdermal delivery of the one or more therapeutic agents contained within the first reservoir ~~for iontophoretic transdermal delivery~~ into the user's skin; and

a second electrode ~~for~~ adapted to electrically ~~coupling~~ couple the second terminal of the power source to the second reservoir, the second electrode operable to conduct electric current between the power source and the second reservoir to ~~ionize~~ promote iontophoretic transdermal delivery of the one or more therapeutic agents contained within the second reservoir ~~for iontophoretic transdermal delivery~~ into the user's skin;

a foldable connecting portion coupling the first end to the second end and adapted to allow the system adapted to be used in an extended or non-extended state, in the extended state the first and second ends being separated by a first predetermined distance with the connecting portion in an unfolded configuration, in the non-extended state the first and second ends being separated by a second distance less than the first distance with the connecting portion in a folded configuration;

placing the system in the extended or non-extended state;

applying electrical current to the therapeutic agents contained in the reservoirs using the power source; and

delivering the therapeutic agents to the user through the user's skin in response to the electrical current.

36. (Original) The method of Claim 35, wherein the first and second reservoirs are adapted to deliver one or more therapeutic agents to one or more portions of a user's body substantially simultaneously.

37. (Original) The method of Claim 35, wherein the system further comprises a protective covering associated with the connecting portion and adapted to be removably coupled to a hypoallergenic adhesive on a bottom of the connecting portion, the hypoallergenic adhesive adapted to removably couple the system to the portion of the user's body.

38. (Original) The method of Claim 35, wherein the system further comprises a protective tab associated with each reservoir, each tab adapted to be removably coupled to a hypoallergenic adhesive associated with its reservoir and further adapted to protect and provide protection from the therapeutic agents in its reservoir prior to application of the system to the user's skin, the hypoallergenic adhesive adapted to removably couple the system to the portion of the user's body.

39. (Original) The method of Claim 35, wherein the first end is associated with a positive terminal of the power source and the second end is associated with a negative terminal of the power source.

40. (Original) The method of Claim 35, wherein each reservoir comprises:  
a reservoir pad adapted to absorb the therapeutic agents to be delivered to the user;  
and  
a reservoir gasket adapted to help contain the therapeutic agents contained in the reservoir pad.

41. (Original) The method of Claim 40, wherein the reservoir gaskets comprise a soft, flexible, foldable, FDA-approved, hypoallergenic foam material.



42. (Original) The method of Claim 40, wherein the reservoir pads comprise a soft, flexible, foldable, absorbent, FDA-approved, hypoallergenic material.

43. (Original) The method of Claim 35, wherein the self-contained power source is a battery.

44. (Original) The method of Claim 43, wherein the battery is a 1.55 volt battery.

45. (Original) The method of Claim 35, wherein the first electrode, the second electrode, and the power source comprise a flex-circuit.

46. (Original) The method of Claim 45, wherein the system further comprises a hidden pocket disposed on the first or second end and adapted to house the connecting portion and at least a portion of the flex-circuit when the system is in the non-extended state.

47. (Original) The method of Claim 35, wherein the system is adapted to be disposable after a single use.

48. (Original) The method of Claim 35, wherein the power source is insulated in a protective covering.

49. (Original) The method of Claim 48, wherein the protective covering comprises a polymer or gel-like substance.

50. (Original) The method of Claim 35, wherein the first electrode, the second electrode, and the power source are disposed between at least one layer of insulating material to protect the user's skin.

51. (Original) The method of Claim 35, wherein the system has a maximum thickness of approximately one-sixteenth of an inch.

52. (Currently Amended) An iontophoretic transdermal delivery system for delivering one or more therapeutic agents into a user's skin, comprising:

first means for containing one or more therapeutic agents;

second means for containing one or more therapeutic agents;

third means for generating electrical current, the third means comprising a first terminal and a second terminal;

fourth means for electrically coupling the first terminal to the first means, the fourth means operable to conduct electric current between the third means and the first means to ~~ionize~~ promote iontophoretic transdermal delivery of the one or more therapeutic agents contained within the first means ~~for iontophoretic transdermal delivery~~ into the user's skin; and

fifth means for electrically coupling the second terminal to the second means, the fifth means operable to conduct electric current between the third means and the second means to ~~ionize~~ promote iontophoretic transdermal delivery of the one or more therapeutic agents contained within the second means ~~for iontophoretic transdermal delivery~~ into the user's skin;

foldable sixth means for coupling the first means to the second means and for allowing the system adapted to be used in an extended or non-extended state, in the extended state the first and second means being separated by a first predetermined distance with the sixth means in an unfolded configuration, in the non-extended state the first and second means being separated by a second distance less than the first distance with the sixth means in a folded configuration.

53. (Currently Amended) A system for iontophoretic transdermal delivery of one or more therapeutic agents into a user's skin, comprising:

a first end comprising a first reservoir for containing one or more therapeutic agents, the first reservoir comprising:

a first reservoir pad adapted to absorb the therapeutic agents to be delivered to the user; and

a first reservoir gasket adapted to help contain the therapeutic agents contained in the reservoir pad;

a second end comprising a second reservoir for containing one or more therapeutic agents, the second reservoir comprising:

a second reservoir pad adapted to absorb the therapeutic agents to be delivered to the user; and

a second reservoir gasket adapted to help contain the therapeutic agents contained in the reservoir pad;

the first and second reservoirs adapted to deliver one or more therapeutic agents to one or more portions of a user's body substantially simultaneously; and

a foldable connecting portion coupling the first end to the second end, the connecting portion housing:

a battery for generating electric current, the battery comprising a positive terminal and a negative terminal;

a first electrode for electrically coupling the positive terminal of the power source to the first reservoir, the first electrode operable to conduct electric current between the power source and the first reservoir to ~~ionize~~ promote iontophoretic transdermal delivery of the one or more therapeutic agents contained within the first reservoir ~~for iontophoretic transdermal delivery~~ into the user's skin; and

a second electrode for electrically coupling the negative terminal of the power source to the second reservoir, the second electrode operable to conduct electric current between the power source and the second reservoir to ~~ionize~~ promote iontophoretic transdermal delivery of the one or more therapeutic agents contained within the second reservoir ~~for iontophoretic transdermal delivery~~ into the user's skin, ~~the battery, the first electrode, and the second electrode together comprising a flex-circuit; and skin:~~

the battery, the first electrode, and the second electrode together comprising a flex-circuit; and

the connecting portion adapted to allow the system to be used in an extended or non-extended state, in the extended state the first and second ends being separated by a first predetermined distance with the connecting portion in an unfolded configuration, in the non-extended state the first and second ends being separated by a second distance less than the first distance with the connecting portion in a folded configuration;

a hidden pocket disposed on the first or second end and adapted to house the connecting portion and at least a portion of the flex-circuit when the system is in a non-extended state.

54. (New) The system of Claim 1, wherein the connecting portion houses the self-contained power source, at least a portion of the first electrode, and at least a portion of the second electrode.

55. (New) The method of Claim 18, wherein the connecting portion houses the self-contained power source, at least a portion of the first electrode, and at least a portion of the second electrode.

56. (New) The method of Claim 35, wherein the connecting portion houses the self-contained power source, at least a portion of the first electrode, and at least a portion of the second electrode.

57. (New) The system of Claim 1, wherein the electric currents ionize the one or more therapeutic agents contained within the reservoirs for iontophoretic transdermal delivery into the user's skin.

58. (New) The method of Claim 18, wherein the electric currents ionize the one or more therapeutic agents contained within the reservoirs for iontophoretic transdermal delivery into the user's skin.

59. (New) The method of Claim 35, wherein the electric currents ionize the one or more therapeutic agents contained within the reservoirs for iontophoretic transdermal delivery into the user's skin.

**Conclusion**

In an effort to expedite issuance of a patent from this Application, Applicant has made amendments to Claims 1, 18, 20, 35, and 52-53 broadening certain aspects and clarifying others. Applicant has also added new Claims 54-59 in keeping with certain of the amendments to claims 1, 18, and 35.

Applicant encloses a check for \$54.00 to cover the cost of filing six additional claims over twenty total. Applicant believes no other fee is due. However, the Commissioner is hereby authorized to charge any additional fee or credit any overpayments to Deposit Account No. 02-0384 of Baker Botts L.L.P.

Early and favorable acceptance of this Application is respectfully requested.

Respectfully submitted,

BAKER BOTTS L.L.P.



Christopher W. Kennerly  
Reg. No. 40,675  
Attorneys for Applicant

CWK/bt

**Correspondence Address:**

Baker Botts L.L.P.  
2001 Ross Avenue, 6th Floor  
Dallas, Texas 75201-2980  
(214) 953-6812

  X   Customer Number

**05073**

Date: 6/30/04